Antifungal resistance among Candida species

被引：41

作者：

Klepser, ME ^{[1
]}

机构：

[1] Ferris State Univ, Coll Pharm, Big Rapids, MI USA

来源：

PHARMACOTHERAPY | 2001年 / 21卷 / 08期

关键词：

D O I：

10.1592/phco.21.12.124S.34511

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Isolation of Candida sp less susceptible to traditional therapies and recovery of increasingly resistant isolates during antifungal therapy are growing problems. It is important for clinicians to be aware of trends and mechanisms responsible for the expression of resistance.

引用

页码：124S / 132S

页数：9

共 86 条

[71]

Vanden Bossche H, 1994, Trends Microbiol, V2, P393, DOI 10.1016/0966-842X(94)90618-1

[72]

VANDEN BOSSCHE H, 1994, J MED VET MYCOL, V32, P189

[73]

VANDENBOSSCHE H, 1987, CRIT REV MICROBIOL, V15, P57

[74] CHARACTERIZATION OF AN AZOLE-RESISTANT CANDIDA-GLABRATA ISOLATE [J].

VANDENBOSSCHE, H ;

MARICHAL, P ;

ODDS, FC ;

LEJEUNE, L ;

COENE, MC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (12) :2602-2610

[75] Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome [J].

vanderHorst, CM ;

Saag, MS ;

Cloud, GA ;

Hamill, RJ ;

Graybill, JR ;

Sobel, JD ;

Johnson, PC ;

Tuazon, CU ;

Kerkering, T ;

Moskovitz, BL ;

Powderly, WG ;

Dismukes, WE ;

Riser, L ;

Thomas, C ;

Lacke, C ;

White, AC ;

Patterson, S ;

Davis, D ;

Flanigan, C ;

Harden, T ;

Phillips, D ;

Ullom, I ;

Vasquez, J ;

McMullen, S ;

Flowers, D ;

Bosha, M ;

Britton, M ;

Fisher, JF ;

Newman, C ;

Willis, B ;

Henderson, H ;

Johnson, E ;

Dungo, L ;

Pierce, M ;

Morgan, M ;

Stern, J ;

Petrosky, N ;

Bamberger, D ;

Farnan, R ;

Feinberg, J ;

Apuzzo, L ;

Royal, W ;

Thompson, S ;

Barrett, K ;

Kauffman, C ;

Gutsch, H ;

McKinsey, D ;

Lee, B ;

Hyslop, N ;

Greenspan, D .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (01) :15-21

[76] Candidemia in cancer patients: A prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC) [J].

Viscoli, C ;

Girmenia, C ;

Marinus, A ;

Collette, L ;

Martino, P ;

Vandercam, B ;

Doyen, C ;

Lebeau, B ;

Spence, D ;

Krcmery, V ;

De Pauw, B ;

Meunier, F .

CLINICAL INFECTIOUS DISEASES, 1999, 28 (05) :1071-1079

[77] MECHANISMS OF ACTION OF 5-FLUOROCYTOSINE [J].

WALDORF, AR ;

POLAK, A .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1983, 23 (01) :79-85

[78] THE GENETIC-BASIS OF RESISTANCE TO 5-FLUOROCYTOSINE IN CANDIDA SPECIES AND CRYPTOCOCCUS-NEOFORMANS [J].

WHELAN, WL .

CRC CRITICAL REVIEWS IN MICROBIOLOGY, 1987, 15 (01) :45-56

[79] The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14 alpha: Demethylase in Candida albicans [J].

White, TC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (07) :1488-1494

[80] Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus [J].

White, TC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (07) :1482-1487

← 1 2 3 4 5 6 7 8 9 →